Bold claim: a single bacterial enzyme could explain why some pneumonia patients suffer life-threatening heart problems, while others recover. But here’s where it gets controversial: this isn’t just about the lungs anymore—it’s about a specific mechanism inside the heart that certain bacteria exploit. The study reveals that a pneumococcal enzyme, zmpB, plays a pivotal role in driving cardiac complications in some pneumonia cases.
Key takeaways:
- Bacterial driver of cardiac complications: Researchers identified zmpB as a critical factor behind serious heart events in pneumonia patients, such as heart failure and heart attacks.
- Mechanism of heart damage: Strains of Streptococcus pneumoniae carrying zmpB, especially with specialized FIVAR domains, invade heart cells more effectively, leading to microlesions and cell death. These effects were demonstrated in mouse models and human heart organoids.
- Future clinical impact: Detecting zmpB-positive strains could enable early risk assessment, closer cardiac monitoring, and the development of vaccines or therapies to prevent pneumonia-related heart damage.
Pneumonia places a heavy burden on healthcare systems, triggering over 1.2 million emergency room visits and more than 41,000 adult deaths in the United States each year. Globally, more than one million children under five die from pneumonia annually. Traditionally viewed as a lung disease, pneumonia can also cause deadly heart problems such as heart failure, arrhythmias, or heart attacks.
Researchers from the University of Maryland School of Medicine (UMSOM) and the Heersink School of Medicine at the University of Alabama at Birmingham identified zmpB as a potential reason why some patients develop heart complications while others do not. Enzymes drive chemical reactions that support bacterial survival, growth, and tissue invasion; thus, zmpB represents a promising target for future vaccines or therapies. The findings were published in Cell Reports on December 4.
“About one in five people hospitalized with pneumonia will experience a life-threatening cardiac event, and even in the following years, they’re at least twice as likely to develop some form of heart failure,” noted Carlos J. Orihuela, PhD, lead author and Professor of Microbiology at UAB.
Though pneumonia can be caused by various bacteria and viruses, the team focused on Streptococcus pneumoniae, the leading cause of community-acquired pneumonia. They used genome-wide association studies, mouse models, and cardiac organoids to confirm that S. pneumoniae can directly damage the heart and that zmpB enhances the bacterium’s ability to invade heart tissue.
“This role for zmpB is entirely new and turns the enzyme into a potential treatment target,” Orihuela added.
Adonis D’Mello, PhD, a bioinformatics analyst in the Tettelin lab at UMSOM, explained the key pattern: patients with heart failure were more often infected with S. pneumoniae strains carrying zmpB with a distinctive feature called FIVAR domains. These domains help bacteria invade and persist in heart cells, creating pockets of infection. More FIVAR domains tended to correlate with greater heart damage.
In mouse experiments, animals infected with a standard pneumonia strain developed numerous cardiac microlesions and heart tissue death, whereas those infected with a zmpB-knockout strain showed far fewer or no such damage.
Human heart organoids exposed to three tests—pneumococcal strains with and without zmpB and various zmpB versions—revealed that strains with zmpB and intact FIVAR domains entered heart cells and caused tissue death. Strains lacking FIVAR domains had significantly reduced bacterial entry and cell death.
Tettelin summarized: heart injury depended on the zmpB variant, and FIVAR-equipped proteins facilitate heart invasion and damage.
Orihuela stated the goal: by decoding these molecular fingerprints, it may become possible to shield patients from cardiac injury during pneumonia or at least lessen its severity. While clinical applications require more work, a genetic test could someday identify high-risk strains early in infection for closer cardiac monitoring or targeted interventions.
Independent expert Mogens Kilian, Emeritus Professor of Medical Microbiology, lauded the work for revealing a previously enigmatic enzyme’s function and its link to serious pneumonia complications. He suggested the study opens a potential path to prevention through targeted strategies.
Controversial edge: if zmpB and its FIVAR domains are as predictive as the study suggests, should routine pneumonia management include rapid genetic profiling of infecting strains to guide cardiac monitoring and treatment decisions? What ethical or logistical hurdles might arise when integrating such testing into standard care? Share your thoughts in the comments.
